QILU Pharma Spain

QILU Pharma Spain currently does not have available carbon emissions data for the most recent year, as no specific figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that QILU Pharma Spain may still be in the early stages of formalising its climate commitments or reporting its emissions. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing carbon emissions and setting reduction targets in line with global climate goals. As such, QILU Pharma Spain may benefit from developing a comprehensive strategy to measure and reduce its carbon footprint, particularly focusing on Scope 1 and Scope 2 emissions, which pertain to direct emissions from owned or controlled sources and indirect emissions from the generation of purchased energy, respectively. Without specific emissions data or reduction initiatives, it is challenging to assess QILU Pharma Spain's current impact on climate change or its commitment to sustainability.